(DLB) Dolby Laboratories - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US25659T1079

DLB: Audio, Imaging, Codecs, Speakers, Amplifiers, Processors

Dolby Laboratories is a leader in audio and imaging technologies, shaping the entertainment experience across various platforms. From cinemas to home devices, Dolbys innovations enhance how we consume media. Their technologies like Dolby Atmos and Dolby Vision are staples in the industry, delivering immersive sound and visuals that redefine entertainment.

The companys portfolio includes a range of audio codecs such as AAC, HE-AAC, and Dolby AC-4, which are crucial for efficient media distribution. Dolby Atmos, their groundbreaking spatial audio technology, has become a standard in both cinemas and home theaters. On the visual side, Dolby Vision offers HDR capabilities that elevate image quality, making it a favorite among content creators and consumers alike.

eyond codecs, Dolby provides a suite of hardware and software solutions. Their digital cinema servers and processors are essential for modern theaters, ensuring high-quality audio and image reproduction. The company also caters to broader markets, including broadcast, gaming, and automotive industries, where their technologies enhance user experiences.

Financially, Dolby Laboratories presents an attractive profile for investors. With a market cap of over $8 billion, the company demonstrates stability and growth potential. The current P/E ratio of 31.29, coupled with a forward P/E of 19.42, suggests confidence in future earnings. A P/S ratio of 6.42 indicates strong revenue generation relative to its market value.

Investors should consider Dolbys consistent innovation and its role as a backbone of the entertainment industry. Their ability to adapt to emerging technologies and expand into new markets positions them as a resilient player in the tech sector. For fund managers, Dolbys financial health and industry leadership make it a compelling addition to a growth-oriented portfolio.

Additional Sources for DLB Stock

DLB Stock Overview

Market Cap in USD 7,866m
Sector Industrials
Industry Specialty Business Services
GiC Sub-Industry Electronic Components
IPO / Inception 2005-02-17

DLB Stock Ratings

Growth 5y 25.1%
Fundamental 44.5%
Dividend 57.9%
Rel. Strength -1.92
Analysts 4.67/5
Fair Price Momentum 73.18 USD
Fair Price DCF 133.86 USD

DLB Dividends

Dividend Yield 12m 1.59%
Yield on Cost 5y 2.54%
Annual Growth 5y 6.93%
Payout Consistency 86.1%

DLB Growth Ratios

Growth Correlation 3m 35.8%
Growth Correlation 12m 24.8%
Growth Correlation 5y 2.5%
CAGR 5y 10.69%
CAGR/Max DD 5y 0.28
Sharpe Ratio 12m -0.54
Alpha -11.29
Beta 1.004
Volatility 20.12%
Current Volume 289.3k
Average Volume 20d 440.2k
What is the price of DLB stocks?
As of April 02, 2025, the stock is trading at USD 80.63 with a total of 289,286 shares traded.
Over the past week, the price has changed by -1.60%, over one month by -1.59%, over three months by +3.23% and over the past year by -2.35%.
Is Dolby Laboratories a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Dolby Laboratories (NYSE:DLB) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 44.46 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DLB as of April 2025 is 73.18. This means that DLB is currently overvalued and has a potential downside of -9.24%.
Is DLB a buy, sell or hold?
Dolby Laboratories has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy DLB.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for DLB stock price target?
According to ValueRays Forecast Model, DLB Dolby Laboratories will be worth about 81.7 in April 2026. The stock is currently trading at 80.63. This means that the stock has a potential upside of +1.38%.
Issuer Forecast Upside
Wallstreet Target Price 100 24%
Analysts Target Price 100 24%
ValueRay Target Price 81.7 1.4%